

DAY 2 FROM CRISIS MANAGEMENT TO VACCINES ERA

8:30-10:00	HEALTHCARE MANAGEMENT Plenary Session	Prof Peter Pitts, USA , Ben Gurion University IL
	<p>CRISIS MANAGEMENT</p> <ol style="list-style-type: none"> 1. At hospital level and national level, what is the best strategy for the specialised units' creation, staff redirecting, and equipment acquisition. 3. World pandemic management: the Lancet Commission Analysis and recommendations 4. Few national strategies across the spectrum: Panel <i>Comparing different regions; defining parameters for efficiency</i> <p>EFFICACY OF NON PHARMACEUTICAL MEASURES</p> <ul style="list-style-type: none"> · Lockdowns and quarantines strategies efficacy · Masks and social distancing · Cases Tracking, Test & Track · Public compliance 	
10:00-10:30	COFFEE BREAK VACCINES Plenary Session	
10:30-12:30	<p>VACCINES: Benefit risk from clinical trials to post marketing surveillance</p> <ul style="list-style-type: none"> · How to assess a benefit risk balance during a crisis? Decision making for special populations: elderly, pregnant women , children · Post marketing surveillance : safety efficiency around the world · How Real-World Data can lead to strategic Public Health Decisions <p>Panel : Digitalisation of medical data</p>	<p>Prof Cyrille Cohen IL</p> <p>Prof Marc Bardou FR</p> <p>Dr Gidi Stein</p> <p>Dr Ariel Israel</p> <p>Limor Epstein</p>
12:30-14:00	LUNCH BREAK	
14:00-15:30	<p>VACCINATION ROLL OUT: Panel - Plenary session</p> <ol style="list-style-type: none"> 1. Logistics aspects to make the vaccines available at a large scale, from manufacturing to shipping. 2. How many boosters and infections to reach the herd immunity? 3. Vaccination deployment strategies: what works best? 	Ministries of Health
15:30 16:00	COFFEE BREAK	
16:00-17:30	<p>VACCINES TECHNOLOGY</p> <ol style="list-style-type: none"> 1. The new technologic platforms 2. Can we win the race of virus mutations and adapt the vaccines on time ? 3. The future of vaccinology 4. The new avenues opened by mRNA in oncology, inflammatory and immune diseases 	Industry